Ausgabe 3/2019
Inhalt (21 Artikel)
The role of thioredoxin system in cancer: strategy for cancer therapy
Jin-Jing Jia, Wen-Shuo Geng, Zhan-Qi Wang, Lei Chen, Xian-Si Zeng
Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
Marie Lindhard Madsen, Hanne Due, Niels Ejskjær, Paw Jensen, Jakob Madsen, Karen Dybkær
Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
Maarten van Eijk, René J. Boosman, Alfred H. Schinkel, Alwin D. R. Huitema, Jos H. Beijnen
Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients
Yvonne Y. Lau, Wen Gu, Yu-Yun Ho, Ying Hong, Xinrui Zhang, Patrick Urban
Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment
Oznur Yigit, Mavis Emel Kulak Kayikci, Cagri Mesut Temucin, Sarp Sarac, Mustafa Erman, Erol Belgin
In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models
Qi Weng, Leilei Zhou, Lihua Xia, Yixin Zheng, Xiangli Zhang, Fengzhi Li, Qingyong Li
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
Whitney P. Kirschbrown, Bei Wang, Ihsan Nijem, Atsushi Ohtsu, Paulo M. Hoff, Manish A. Shah, Lin Shen, Yoon-Koo Kang, Maria Alsina, Sandhya Girish, Amit Garg
Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells
Aehtesham Hussain, Mohd Saleem Dar, Nasima Bano, Md Mehedi Hossain, Rafia Basit, Aadil Qadir Bhat, Mushtaq A. Aga, Sabeena Ali, Qazi Parvaiz Hassan, Mohd Jamal Dar
Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study
Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
Sanjay Goel, Umang Swami, Kirushna Kumar, Christian Dittrich, Larisa Reyderman, Minish Jain, Joseph Aisner, James Song, Daniel P. Petrylak
Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors
Rex M. Philpot, M. Ficken, B. E. Johns, M. E. Engberg, L. Wecker
Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
Sofya Pintova, Sirish Dharmupari, Erin Moshier, Nicole Zubizarreta, Celina Ang, Randall F. Holcombe
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients
Xuan Jin, Yu Bai, Lan Gao, Shikai Wu
A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer
Lu Cao, Guomin Xiang, Fang Liu, Cong Xu, Jing Liu, Qingxiang Meng, Shuhua Lyu, Shuling Wang, Yun Niu
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors
Elodie Valade, Anne-Gaëlle Dosne, Hong Xie, Robert Kleiman, Lilian Y. Li, Juan José Perez-Ruixo, Daniele Ouellet
Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response
Xing Xu, Guoliang Zheng, Tao Zhang, Yan Zhao, Zhichao Zheng
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients
Utako Ishimoto, Akiyoshi Kinoshita, Yuki Hirose, Keiko Shibata, Ayako Ishii, Ryo Shoji, Takeharu Yokota, Akira Iwaku, Yusuke Mizuno, Kazuhiko Koike, Masayuki Saruta
Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
Mie Kotake, Hisao Imai, Kyoichi Kaira, Tomomi Fujisawa, Yasuhiro Yanagita, Koichi Minato
Rituximab dosing in hematological malignancies: an old question, revisited
Peter N. Morcos, Axel Boehnke, Nancy Valente, Donald E. Mager
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin